C4x Discovery Share Discussion Threads

[bamboozler] 12/4/2021 08:19

Great to see another partnership announced and the as Alloa points out it confirms C4X was not just a one hit wonder.

[davemac3] 12/4/2021 08:18

the fact that there are preclinical milestones suggests this is not ready for phase1 yet, it could still fail. Hopefully NRF2 is still in play and they do a deal soon.

[alloa2003] 12/4/2021 08:08

Without the fund raising dilution we would have been a lot higher then again without the extra funds the company would not have survived.

Not only is the deal potentially huge but this confirms the system works - one big deal might have been seen as a fluke but two shows the system works. Obv both deals need to pass cinical trials, etc but Clive Dix always saids he was confident they would pass preclinical trials as not new treatments, just new methods of delivery.

[alloa2003] 12/4/2021 08:03

Well worth the wait and more to follow hopefully - as mentioned, this was not the deal we were expecting.

[davemac3] 12/4/2021 07:15

Interesting that there are preclinical milestones. also not the deal we were expecting

[ayl30] 12/4/2021 07:10

Today's rns looks a splendid deal

[astorcourt] 06/4/2021 09:10

sickle cell disease getting some media attention through the unfortunate disappearance of london schoolboy, who carries the disease.

c4xd at the forefront of finding remedies to tackle this disease.

[alloa2003] 22/3/2021 23:46

Just checking, aside from the interim and final results, we have not had a business update on its own since 01 Oct 2019. There was an update on the INDV clinical trials on 09 Dec 2019 but other than that the news flow has been poor. Oh yes, we have had placing news but no business updates other than with the half year and full year results.

Sometimes I wish they were a little more open with what is happening behind the scenes rather than leaving the market in the dark.

[alloa2003] 22/3/2021 22:31

Interesting that the shares seem very steady even when things go quiet - havent yet seen any real profit taking. Is there still demand for the shares behind the scenes?

[bloomberg2] 17/3/2021 07:54

https://www.rpharms.com/resources/podcast-central/pharmsci-today

[alloa2003] 16/3/2021 21:51

Even clarifying the maximum income for the INDV deal would see the share price rocket. One or two more deals of that size would put us in a different league. The kicker with this company will be the cumulatve repetitive income from each individual molecule going forwards.

[t0pgrader] 16/3/2021 14:28

@Toffee. CD was very particular with his choice of words in his last video in 2020. He said we could expect "two or maybe three deals in the next few years" and if I remember correctly he qualified that by saying they should be approximately the same size as the Indivior licence deal.

[toffeeman] 16/3/2021 11:44

Three deals a year! None since that video at the end of 2018

[alloa2003] 16/3/2021 11:17

He has been making all of the right noises for years, just needs to deliver now. On balance I think he will deliver. However, his approach is not news driven which drives share prices. We will only hear about deals when they have been signed.

[bloomberg2] 15/3/2021 22:03

https://youtu.be/ntljiVNXgvI

[alloa2003] 15/3/2021 20:54

Makes you wonder if there has been a stock overhang for a while and it is just being cleared now.

[ayl30] 15/3/2021 15:00

Nice move again today

[alloa2003] 15/3/2021 14:26

There are some chunky share deals going through. There must be huge demand in the background to mop these sales up.

I would love to know what is going on behind the scenes.

[bloomberg2] 15/3/2021 11:04

Interim results due end of April! Nothing price sensitive usually made with interims and final results!!

[astorcourt] 15/3/2021 10:48

Will the company issue an operational update this year?

[bloomberg2] 15/3/2021 09:48

Big punting again

[bloomberg2] 13/3/2021 16:44

https://www.wired.co.uk/article/using-vr-to-discover-new-life-saving-drugs

[bloomberg2] 13/3/2021 16:43

Lock and keyMolecules change shape all the time. In drug discovery, you're looking for the molecule which has the right shape as often as possible. Having the 'right shape' means both that it is more likely to bind to the protein in question – so, for instance, the orexin receptor, governing craving – and treat the associated issue, as well as have the fewest side-effects. While molecules change shape all the time, some will have the right shape more often than others – and it's this you're looking to find.Craig Fox, chief scientific officer at C4XD, uses the 'lock and key' analogy to sketch this out. "You've got a lock inside your body which is the protein that the drug targets – drugs generally target one protein in the body," he says. You're trying to find the absolute best key to bind to that protein. The idea is to then map the protein's structure, looking at "known keys" that successfully bind to it and treat it. These known keys may not work extremely well, but do still interact. This is your starting point; from here, you refine.You can use these inexact models to imagine what might make the best 'key' in an ideal world, treating the disease more exactly and causing fewer side effects. In the case of orexin, you want a drug that can interrupt craving but not mess with wakefulness. Chemists work with the belief that a specific formation of the molecule (called a 'conformation,' where atoms in a molecule rotate can around a chemical bond to form subtly-new structures) will be able to do this: bind with the receptor but not mess with other functions.C4X DiscoveryIt is always a process of trial and error – from early iterations to eventual drug trials – to find which molecule works best. C4XD says their VR technology, along with the greater detail they have about each molecule and its shapes, reduces the margin of error in their part in the drug discovery process: the phases of experimentation before a drug goes to trial in humans.

[bloomberg2] 13/3/2021 16:41

https://youtu.be/DUn21r309dc